Plasminogen activator inhibitor-1 4G/5G genetic polymorphism does not affect peritoneal transport characteristic.

There is evidence that type 1 plasminogen activator inhibitor (PAI-1) may have an important role in peritoneal function. We studied the effect of physiologically relevant PAI-1 promotor polymorphisms on peritoneal permeability. We performed a standard peritoneal equilibration test (PET) in 100 new continuous ambulatory peritoneal dialysis (CAPD) patients. We studied another 48 prevalent CAPD patients who had a baseline PET performed 2 years before; a standard PET was repeated on enrollment. The PAI-1 promotor polymorphism was examined. All patients then were followed up for 16.7 +/- 15.0 months. Prevalences of 4G/4G, 4G/5G, and 5G/5G genotypes were 31.8%, 46.6%, and 21.6%, respectively. Of the 100 new CAPD patients, there was no difference in net ultrafiltration (UF), dialysate-plasma (D/P) creatinine ratio at 4 hours, or mass transfer area coefficient (MTAC) of creatinine among the three genotype groups. D/P creatinine ratios at 4 hours were 0.595 +/- 0.133, 0.607 +/- 0.137, and 0.627 +/- 0.142 for the 4G/4G, 4G/5G, and 5G/5G groups, respectively (one way analysis of variance, P = 0.715). Of the 48 prevalent patients, PAI-1 genotype did not affect the longitudinal change in net UF, D/P creatinine ratio at 4 hours, or MTAC of creatinine. During follow-up, 16 patients developed peritonitis episodes that required Tenckhoff catheter removal. One patient died, 8 patients returned to long-term CAPD therapy after peritonitis resolved, and the other 7 patients developed peritoneal failure and were switched to long-term hemodialysis therapy. PAI-1 promotor genotype did not predict peritoneal failure after an episode of severe peritonitis (chi-square test, P = 0.328). We conclude that PAI-1 promotor polymorphism is not associated with peritoneal transport characteristics in stable peritoneal dialysis patients, longitudinal change in peritoneal transport, or development of peritoneal failure after an episode of severe peritonitis.

[1]  E. Rondeau,et al.  Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis. , 2000, Kidney international.

[2]  J. Strackee,et al.  Simple assessment of the efficacy of peritoneal transport in continuous ambulatory peritoneal dialysis patients. , 1986, Blood purification.

[3]  S. Humphries,et al.  The 4G/5G Genetic Polymorphism in the Promoter of the Plasminogen Activator Inhibitor-1 (PAI-1) Gene Is Associated with Differences in Plasma PAI-1 Activity but not with Risk of Myocardial Infarction in the ECTIM Study , 1995, Thrombosis and Haemostasis.

[4]  J. Chan,et al.  Association of plasminogen activator inhibitor-1 4G/4G genotype and type 2 diabetic nephropathy in Chinese patients. , 2000, Kidney international.

[5]  T. Kooistra,et al.  Modulation of procoagulant and fibrinolytic system components of mesothelial cells by inflammatory mediators. , 1996, The American journal of physiology.

[6]  W. Knowler,et al.  Diabetic Retinopathy, Promoter (4G/5G) Polymorphism of PAI-1 Gene, and PAI-1 Activity in Pima Indians With Type 2 Diabetes , 1997, Diabetes Care.

[7]  R. Westrick,et al.  Plasminogen Activator Inhibitor-1 Regulates Tumor Growth and Angiogenesis* , 2001, The Journal of Biological Chemistry.

[8]  H. Schnaper,et al.  Plasminogen activators augment endothelial cell organization in vitro by two distinct pathways , 1995, Journal of cellular physiology.

[9]  M. Rocco,et al.  24-Hour Dialysate Collection for Determination of Peritoneal Membrane Transport Characteristics: Longitudinal Follow-Up Data for the Dialysis Adequacy and Transport Test (Datt) , 1996, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[10]  S. Opatrná,et al.  Tissue-Type Plasminogen Activator (tPA) and Its Inhibitor (PAI-1) in Patients Treated with Continuous Ambulatory Peritoneal Dialysis , 1998, American Journal of Nephrology.

[11]  J. Rakic,et al.  Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[12]  T. Takahara,et al.  Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: role of stellate cells. , 1999, Journal of hepatology.

[13]  S. Duffy,et al.  Repeat measurement of case-control data: corrections for measurement error in a study of ischaemic stroke and haemostatic factors. , 1997, International journal of epidemiology.

[14]  M. Horton,et al.  Regulation of plasminogen activator inhibitor-1 and urokinase by hyaluronan fragments in mouse macrophages. , 2000, American journal of physiology. Lung cellular and molecular physiology.

[15]  R. Selgas,et al.  Tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-I (PAI-I) levels in plasma and peritoneal effluent in patients on CAPD. , 1992, Advances in peritoneal dialysis. Conference on Peritoneal Dialysis.

[16]  T. Urano,et al.  FLUCTUATION OF TPA PAI-1 LEVELS IN PLASMA : DIFFERENCE OF THEIR FLUCTUATION PATTERNS BETWEEN MALE AND FEMALE , 1990 .

[17]  C. Cheung,et al.  Interference of creatinine measurement in CAPD fluid is dependent on glucose and creatinine concentrations. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[18]  P. Li,et al.  Peritoneal transport status correlates with morbidity but not longitudinal change of nutritional status of continuous ambulatory peritoneal dialysis patients: a 2-year prospective study. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[19]  H. Shimada,et al.  Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectin. , 2001, Cancer research.

[20]  J. Yudkin,et al.  Determinants of Plasminogen Activator Inhibitor 1 Activity in Treated NIDDM and Its Relation to a Polymorphism in the Plasminogen Activator Inhibitor 1 Gene , 1995, Diabetes.

[21]  D. Noe.  A body surface area nomogram based on the formula of Gehan and George. , 1991, Journal of pharmaceutical sciences.

[22]  P. Li,et al.  Importance of dialysis adequacy in mortality and morbidity of chinese CAPD patients. , 2000, Kidney international.

[23]  T. Urano,et al.  Fluctuation of TPA and PAI-1 antigen levels in plasma: difference of their fluctuation patterns between male and female. , 1990, Thrombosis research.

[24]  W. Hahn,et al.  Mesosecrin: a secreted glycoprotein produced in abundance by human mesothelial, endothelial, and kidney epithelial cells in culture , 1987, The Journal of cell biology.

[25]  Douglas G. Altman,et al.  Practical statistics for medical research , 1990 .

[26]  C. Patlak,et al.  Correlations between Plasminogen Activator Inhibitor-1 and Peritoneal Transport in Pediatric Ccpd Patients , 1995 .

[27]  B. Risberg,et al.  Plasminogen activators and inhibitors in peritoneal tissue , 1997, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[28]  B. Piraino,et al.  Peritoneal dialysis-related peritonitis treatment recommendations: 1996 update. , 1996, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[29]  R. Diegelmann,et al.  Differential regulation of PAI-1 gene expression in human fibroblasts predisposed to a fibrotic phenotype. , 1999, Experimental cell research.

[30]  B. Risberg,et al.  Tissue markers as predictors of postoperative adhesions , 1998, The British journal of surgery.

[31]  P. Grant,et al.  Plasminogen Activator Inhibitor-1 (PAI-1) Promoter Polymorphism and Coronary Artery Disease in Non-Insulin-Dependent Diabetes , 1995, Thrombosis and Haemostasis.

[32]  M. Spannagl,et al.  Coagulation and Fibrinolysis-Related Antigens in Plasma and Dialysate of Capd Patients , 1997, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[33]  B. Piraino,et al.  Adult Peritoneal Dialysis-Related Peritonitis Treatment Recommendations: 2000 Update , 2000, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.